[{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cefiderocol","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cefiderocol","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cefiderocol","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Monaldi Hospital | Rutgers Robert Wood Johnson Medical School | Pisa University Hospital | Assaf-Harofeh Medical Center | Sheba Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cefiderocol","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Monaldi Hospital | Rutgers Robert Wood Johnson Medical School | Pisa University Hospital | Assaf-Harofeh Medical Center | Sheba Medical Center","highestDevelopmentStatusID":"11","companyTruncated":"Rambam Health Care Campus \/ Monaldi Hospital | Rutgers Robert Wood Johnson Medical School | Pisa University Hospital | Assaf-Harofeh Medical Center | Sheba Medical Center"},{"orgOrder":0,"company":"Hartford Hospital","sponsor":"Shionogi | Keystone Bioanalytical | Indiana University Health Methodist Hospital | University of Pittsburgh Medical Center | University of Texas System","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cefiderocol","moa":"Bacterial penicillin-binding protein","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Hartford Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hartford Hospital \/ Shionogi | Keystone Bioanalytical | Indiana University Health Methodist Hospital | University of Pittsburgh Medical Center | University of Texas System","highestDevelopmentStatusID":"11","companyTruncated":"Hartford Hospital \/ Shionogi | Keystone Bioanalytical | Indiana University Health Methodist Hospital | University of Pittsburgh Medical Center | University of Texas System"},{"orgOrder":0,"company":"Hartford Hospital","sponsor":"Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cefiderocol","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Hartford Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hartford Hospital \/ Shionogi","highestDevelopmentStatusID":"6","companyTruncated":"Hartford Hospital \/ Shionogi"},{"orgOrder":0,"company":"Qpex Biopharma","sponsor":"Shionogi | Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Cefiderocol","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Qpex Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qpex Biopharma \/ Shionogi | Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"6","companyTruncated":"Qpex Biopharma \/ Shionogi | Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Joseph Kuti","sponsor":"Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cefiderocol","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Joseph Kuti","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Joseph Kuti \/ Shionogi","highestDevelopmentStatusID":"6","companyTruncated":"Joseph Kuti \/ Shionogi"}]

Find Clinical Drug Pipeline Developments & Deals for Cefiderocol

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Cefiderocol is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Bacterial Infections.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 05, 2025

                          Lead Product(s) : Cefiderocol

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Shionogi | Biomedical Advanced Research and Development Authority

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Cefiderocol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gram-Negative Bacterial Infections.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 17, 2023

                          Lead Product(s) : Cefiderocol

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Lead Product(s) : Cefiderocol

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase IV

                          Sponsor : Monaldi Hospital | Rutgers Robert Wood Johnson Medical School | Pisa University Hospital | Assaf-Harofeh Medical Center | Sheba Medical Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Cefiderocol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Carbapenem-resistant Bacterial Infections.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 28, 2023

                          Lead Product(s) : Cefiderocol

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Monaldi Hospital | Rutgers Robert Wood Johnson Medical School | Pisa University Hospital | Assaf-Harofeh Medical Center | Sheba Medical Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Hartford Hospital

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Hartford Hospital

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Details : Cefiderocol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 13, 2022

                          Lead Product(s) : Cefiderocol

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Shionogi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Hartford Hospital

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Hartford Hospital

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Lead Product(s) : Cefiderocol

                          Therapeutic Area : Genetic Disease

                          Study Phase : Phase IV

                          Sponsor : Shionogi | Keystone Bioanalytical | Indiana University Health Methodist Hospital | University of Pittsburgh Medical Center | University of Texas System

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Cefiderocol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cystic Fibrosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 06, 2022

                          Lead Product(s) : Cefiderocol

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase IV

                          Sponsor : Shionogi | Keystone Bioanalytical | Indiana University Health Methodist Hospital | University of Pittsburgh Medical Center | University of Texas System

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Joseph Kuti

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Joseph Kuti

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Details : Cefiderocol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Sepsis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 09, 2021

                          Lead Product(s) : Cefiderocol

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Shionogi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Cefiderocol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gram-Negative Bacterial Infections.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 06, 2020

                          Lead Product(s) : Cefiderocol

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Cefiderocol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gram-Negative Bacterial Infections.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 02, 2020

                          Lead Product(s) : Cefiderocol

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          University of Queensland

                          Country arrow
                          PackExpo
                          Not Confirmed

                          University of Queensland

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Details : Cefiderocol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sepsis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 11, 2019

                          Lead Product(s) : Cefiderocol

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Shionogi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Cefiderocol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pneumonia, Bacterial.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 05, 2019

                          Lead Product(s) : Cefiderocol

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank